In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on BioNTech SE (BNTX – Research Report), with a price target of $194.00. The company’s shares closed last Friday at $160.42, close to its 52-week low of $117.08.
According to TipRanks.com, Harrison is a 5-star analyst with an average return of 7.4% and a 52.0% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Centessa Pharmaceuticals, BioMarin Pharmaceutical, and Vertex Pharmaceuticals.
Currently, the analyst consensus on BioNTech SE is a Moderate Buy with an average price target of $224.18, which is a 44.1% upside from current levels. In a report issued on July 1, Deutsche Bank also maintained a Hold rating on the stock with a $180.00 price target.
Based on BioNTech SE’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $6.37 billion and net profit of $3.7 billion. In comparison, last year the company earned revenue of $2.05 billion and had a net profit of $1.13 billion.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
BioNTech SE is a Germany-based biotechnology company that develops and manufactures immunotherapies for cancer, infectious diseases, allergies and autoimmune disorders.
Read More on BNTX:
- Morgan Stanley Maintains a Buy Rating on Agiliti (AGTI)
- Axonics Modulation Technologies (AXNX) Receives a Buy from Morgan Stanley
- Rhythm Pharmaceuticals (RYTM) Gets a Hold Rating from Morgan Stanley
- BeiGene (BGNE) Gets a Buy Rating from Morgan Stanley
- JMP Securities Reaffirms Their Buy Rating on Enova International (ENVA)